Hennion & Walsh Asset Management Inc. Grows Stock Holdings in Urogen Pharma $URGN

Hennion & Walsh Asset Management Inc. raised its holdings in shares of Urogen Pharma (NASDAQ:URGN) by 69.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,183 shares of the company’s stock after acquiring an additional 26,828 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Urogen Pharma were worth $1,300,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in URGN. AQR Capital Management LLC raised its stake in Urogen Pharma by 347.5% during the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after purchasing an additional 88,577 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after buying an additional 1,653 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Urogen Pharma by 216.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock worth $48,227,000 after buying an additional 2,983,368 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Urogen Pharma by 94.3% during the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock worth $566,000 after acquiring an additional 24,839 shares during the last quarter. Finally, Truist Financial Corp bought a new position in shares of Urogen Pharma during the second quarter worth $423,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the sale, the insider directly owned 139,025 shares of the company’s stock, valued at $3,475,625. This trade represents a 6.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on URGN shares. D. Boral Capital reiterated a “buy” rating and issued a $33.00 price target on shares of Urogen Pharma in a report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Urogen Pharma in a research report on Monday, October 27th. Finally, Wall Street Zen raised Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Urogen Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $33.00.

Urogen Pharma Stock Down 9.5%

Urogen Pharma stock opened at $21.25 on Friday. The company’s 50-day moving average price is $23.74 and its 200-day moving average price is $19.79. The company has a market cap of $994.71 million, a PE ratio of -6.14 and a beta of 1.29. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $30.00.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.03. The business had revenue of $27.48 million during the quarter, compared to the consensus estimate of $34.09 million. As a group, sell-side analysts expect that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.